Apnimed closes upsized IPO, raising $220.8 million
Apnimed Inc. successfully closed its initial public offering on August 3, 2026, securing $220.8 million in gross proceeds through the sale of 13.8 million shares at $16 per share. The deal included the full exercise of an over-allotment option by underwriters BofA Securities, Evercore ISI, Cantor Fitzgerald & Co., and LifeSci Capital. The capital will fund the advancement of AD109, a Phase 3-complete oral treatment for obstructive sleep apnea, ahead of its February 28, 2027 PDUFA decision date.
*this image is generated using AI for illustrative purposes only.
Apnimed Inc., a late-stage clinical pharmaceutical company focused on sleep-related breathing diseases, closed its upsized initial public offering (IPO) on August 3, 2026, raising $220.8 million in gross proceeds. The Cambridge, Massachusetts-based firm sold an aggregate of 13,800,000 shares of common stock at $16.00 per share, including the full exercise by underwriters of their option to purchase an additional 1,800,000 shares. This capital infusion supports the commercialization of its lead candidate, AD109, which targets obstructive sleep apnea (OSA) and has a Prescription Drug User Fee Act (PDUFA) goal date of February 28, 2027.
The offering was managed by BofA Securities, Evercore ISI, Cantor Fitzgerald & Co., and LifeSci Capital as joint book-running managers. Apnimed’s common stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol APMD. Registration statements for the offering were filed with the Securities and Exchange Commission (SEC) and became effective on July 30, 2026. All shares in the offering were sold by Apnimed itself, not by selling shareholders.
Offering Details
| Metric | Value |
|---|---|
| Total Shares Sold | 13,800,000 |
| Price Per Share | $16.00 |
| Gross Proceeds | $220.8 million |
| Base Offering Shares | 12,000,000 |
| Option Shares Exercised | 1,800,000 |
| Trading Start Date | July 31, 2026 |
| Closing Date | August 3, 2026 |
Clinical Context
Apnimed is developing AD109, a novel oral therapy designed to improve oxygenation in patients with mild, moderate, and severe OSA. The company believes that once-nightly oral drugs can expand treatment reach compared to traditional devices or surgeries. AD109 has completed two Phase 3 clinical trials. The PDUFA date of February 28, 2027, marks the deadline for regulatory decision-making by the FDA regarding the New Drug Application.
What the Numbers Show
The full exercise of the underwriters’ option indicates strong investor demand, increasing the total capital raised from the initial $192 million target to $220.8 million. This additional liquidity provides a more robust runway for Apnimed to navigate the final stages of regulatory approval and prepare for commercial launch. With no revenue disclosed from operations yet, the capital infusion is critical for sustaining development costs until potential market entry post-PDUFA date.
How might the full exercise of the underwriters' option influence Apnimed's stock volatility and institutional investor confidence in the months leading up to the PDUFA date?
What specific commercialization strategies is Apnimed planning to deploy to capture market share from established CPAP device manufacturers once AD109 receives FDA approval?
Given the $220.8 million raise, what is Apnimed's projected cash runway, and will additional capital raises be necessary to sustain operations through the initial commercial launch phase?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
